Compare Amphastar Pharmaceuticals Inc (AMPH) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Royal Caribbean Cruises Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Royal Caribbean Cruises Ltd trades at $307.2 (market cap $82.38B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 95.4× Amphastar Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RCL | |
|---|---|---|
Market Cap | $863.95M | $82.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $365.84 |
52-Week Low | $16.87 | $246.71 |
Enterprise Value | $1.26B | $105.02B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Royal Caribbean Group (RCL) trades at $320, down 0.17% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by robust earnings beats, with Q2 2026 EPS of $4.21 exceeding the $3.98 estimate, and a consensus analyst price target of $343.09 implying upside. Recent news highlights strong demand, fleet expansion, and a $1.25 billion senior notes offering to fund growth, while cash flow trends show improving operational strength.
The outlook for RCL remains positive, driven by record bookings, pricing power, and strategic investments, though risks include geopolitical impacts on European itineraries, high debt levels, and premium valuations. Investors should weigh the company's solid execution against macroeconomic and industry-specific headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
